Literature DB >> 12407406

Cancer immunoediting: from immunosurveillance to tumor escape.

Gavin P Dunn1, Allen T Bruce, Hiroaki Ikeda, Lloyd J Old, Robert D Schreiber.   

Abstract

The concept that the immune system can recognize and destroy nascent transformed cells was originally embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas. This hypothesis was abandoned shortly afterwards because of the absence of strong experimental evidence supporting the concept. New data, however, clearly show the existence of cancer immunosurveillance and also indicate that it may function as a component of a more general process of cancer immunoediting. This process is responsible for both eliminating tumors and sculpting the immunogenic phenotypes of tumors that eventually form in immunocompetent hosts. In this review, we will summarize the historical and experimental basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407406     DOI: 10.1038/ni1102-991

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  1455 in total

1.  Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.

Authors:  Salem Chouaib
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Authors:  Casey W Shuptrine; Reham Ajina; Elana J Fertig; Sandra A Jablonski; H Kim Lyerly; Zachary C Hartman; Louis M Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-02       Impact factor: 6.968

Review 3.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

4.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

5.  A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Nancy L Bartlett; Alex F Herrera; Eva Domingo-Domenech; Amitkumar Mehta; Andres Forero-Torres; Ramon Garcia-Sanz; Philippe Armand; Sumana Devata; Antonia Rodriguez Izquierdo; Izidore S Lossos; Craig Reeder; Taimur Sher; Robert Chen; Sylvia E Schwarz; Leila Alland; Andras Strassz; Kim Prier; Cassandra Choe-Juliak; Stephen M Ansell
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 6.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.

Authors:  Ahmad Al-Sukaini; Francis J Hornicek; Zachary S Peacock; Leonard B Kaban; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2017-07-19       Impact factor: 4.176

Review 9.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 10.  The tumour glyco-code as a novel immune checkpoint for immunotherapy.

Authors:  Ernesto RodrÍguez; Sjoerd T T Schetters; Yvette van Kooyk
Journal:  Nat Rev Immunol       Date:  2018-02-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.